◈ Nootpedia
Compact view
Research pass: medium AAS · Oil injectable SKIP-FOR-NOW MEDIUM

Masteron Enanthate

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

Cosmetic-AAS archetype with zero modern clinical evidence base for healthy adults — entirely a bodybuilding "show prep hardening" compound used in low-body-fat states for aesthetic vasculature/dryness. No cognitive, athletic-performance, recovery, or longevity case. Same-family AAS skip-at-20 logic applies: HPG suppression during ongoing axis maturation (peak HPG at 20yo), atherogenic lipid changes (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid profile worse on this dimension), accelerated androgenic alopecia in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class), gray-market supply chain with high counterfeit rates. For Dylan (20yo MMA athlete, brain-priority, no contest-prep aesthetic goal), Masteron addresses no problem he has and produces no benefit he wants. Verdict reverses ONLY for older bodybuilder in active contest preparation with documented medical supervision — irrelevant to Dylan now or ever (combat sport ≠ bodybuilding aesthetics).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, MMA athlete with peak endogenous T (Dylan-archetype)
    SKIP-AT-

    Same-family AAS logic + the additional point that drostanolone is a purely cosmetic compound for stage aesthetics. Combat sport ≠ bodybuilding aesthetics; the "hardening" effect addresses no problem Dylan has. No cognitive benefit, no meaningful athletic performance benefit, no recovery benefit, real HPG suppression risk during axis maturation, accelerated hair loss in predisposed users, atherogenic lipid changes (worse on HDL than aromatizing AAS), gray-market supply chain. Reconsider only post-30 if competitive bodybuilding ever becomes a goal — clinically implausible for Dylan.

  • 20-30 with documented severe catabolic indication
    N

    drostanolone has no FDA-approved catabolic indication; oxandrolone or testosterone replacement would be considered instead.

  • 30-50, executive maintenance with documented hypogonadism
    SKIP

    TRT is the appropriate intervention, not Masteron. Drostanolone has no place in HRT protocols.

  • 30-50, bodybuilder in active contest preparation, with medical supervision
    OPTIONAL

    niche — the canonical use case for drostanolone. Run with test base, bloodwork monitoring, and recognition of HPG / lipid / hair / cardiac costs. Genuinely cosmetic; no health upside; only justifiable if competitive aesthetic is the explicit goal.

  • 50+, mild cognitive decline
    SKIP

    no indication; cardiovascular + lipid risk outweighs marginal cosmetic gains.

  • Anxiety-prone
    SKIP

    DHT-class CNS effects can drive irritability / aggression / mood lability in susceptible users.

  • High athletic load, tested status (NCAA, USADA, WADA, professional combat sport)
    SKIP-PERMANENT

    during testing window — S1.1 banned, weeks-to-months detection window via urine LC-MS/MS for long-ester injectable.

  • DylanHigh athletic load, untested status (Dylan)
    SKIP

    as default. The risk profile (HPG suppression, atherogenic dyslipidemia, hair loss, gray-market supply) is independent of testing status. The compound provides no athletic performance benefit relevant to combat sport.

  • Sleep-disordered
    SKIP

    Address sleep first; drostanolone has no role and may modestly disturb sleep.

  • Recovery-focused (post-injury, post-illness, healthy young)
    SKIP

    for healthy young. BPC-157, TB-500 are far better-fit for injury recovery without HPG / lipid / hair costs.

  • Strength/anabolic-focused
    SKIP

    drostanolone is not a strength compound. If a strength-focused AAS conversation ever opens (it shouldn't at 20), testosterone enanthate is the more cost-effective and better-evidenced option, and even that is SKIP-AT-20.

  • Cosmetic / contest-prep focused
    T

    canonical use case. This is what the compound is for. Even here, it's a cosmetic specialty with health costs; not appropriate for casual aesthetics.

▸ Subjective experience (deep)

At bodybuilder doses (200-400mg/week enanthate, 8-12 week run typically in contest prep)

  • Week 1-2: Subtle. Most users report "nothing happening yet" — this is consistent with the compound's modest absolute anabolic potency. Distinguishes Masteron from harsher cosmetic compounds (trenbolone) which produce immediate dramatic effects.
  • Week 2-4: First subjective signals — slightly fuller / harder muscle appearance under low body fat conditions; "tighter" feel; slight increase in vascularity at low body fat. Strength gains minimal.
  • Week 4-8: Peak cosmetic effect — visible "hardening" in low-body-fat states (8% or below for men): more striated muscle bellies, more pronounced vascularity, reduced subcutaneous water (already low) appears further reduced. Mood typically neutral or mildly elevated; some users report mild aggression / drive elevation (DHT-class CNS effect). Libido often preserved or modestly elevated early-cycle (DHT-class), then degrades later as endogenous T suppresses without test base.
  • Week 8-12: Full aesthetic effect on stage / in mirror; bloodwork typically shows lipid degradation (HDL drop), mild HPG suppression, mild transaminase elevation (less than orals).
  • Post-cycle: HPG recovery typically 4-8 weeks if cycle was short and PCT run; longer if Masteron run solo without test base (worse HPG outcome).

Characteristic effects

  • "Dry / hard / vascular / striated" — the entire reason the compound is run
  • Minimal water retention (vs aromatizing AAS)
  • Modest libido shifts (initially up, later down)
  • Mild aggression / drive elevation in some users (DHT-class CNS)
  • Hair shedding / scalp thinning in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class)
  • Acne / oily skin in susceptible users (sebaceous gland AR activation)
  • No "fullness" or "pump" beyond what training + nutrition produces

What users do NOT report

  • Significant muscle gain (it's not that compound)
  • Significant strength gain
  • Cognitive enhancement
  • Recovery acceleration
  • Fat loss beyond what diet produces
  • The compound does not "do anything" if body fat is not already low — at 15%+ body fat, the cosmetic effect is invisible
▸ Tolerance + cycling deep dive
  • Tolerance buildup: AR receptor downregulation occurs with all AAS — not "tolerance" in CNS sense, but receptor saturation/downregulation creates diminishing returns past 8-12 weeks. Drostanolone-specific tolerance not well-characterized but follows standard AAS pattern.
  • Recommended cycle (bodybuilder convention): 8-12 weeks on, equal time off; rarely run >12 weeks because the cosmetic effect is contest-specific (run only when the user is at low body fat for show prep).
  • Reset protocol: Off-cycle 8-12 weeks minimum; PCT (clomid + nolvadex, or enclomiphene) typically starts 1-2 weeks post-cycle and runs 4-6 weeks. HPG axis recovery generally faster than longer-acting injectables but slower than the "mild AAS doesn't suppress" myth implies.
▸ Stacking deep dive

Synergistic with (in bodybuilder protocols, NOT recommended for Dylan)

  • testosterone-cypionate / testosterone enanthate: Almost always run with test base; without it, mid-cycle hypogonadism symptoms (low libido, fatigue, mood drop) emerge. Test base is non-negotiable for any meaningful drostanolone cycle.
  • trenbolone: Synergistic for cutting / contest prep — drostanolone "hardens," trenbolone "shreds"; together produce the harshest cosmetic effect at the highest cardiovascular and neurological cost. Compound risks dramatically.
  • oxandrolone (oral): Sometimes added late-cycle for additional "dryness" — compounds DHT-class side effects (HDL crash, hair loss) without proportional benefit.
  • GH / IGF-1: Adds anabolic synergy; compounds cancer / cardiomyopathy / hypoglycemia risks.

Avoid stacking with

  • Other DHT-derivatives (methenolone, winstrol, oxandrolone): Stacking multiple DHT-class compounds compounds androgenic side effects (hair, skin, prostate) and lipid impact without proportional muscle-building gain. Particularly bad for hair-loss-predisposed users.
  • Nandrolone / 19-nors: No direct contraindication but stacking creates pharmacological mess (different mechanism profiles, harder to attribute side effects); not commonly run together.
  • Aromatase inhibitors (anastrozole, letrozole): Drostanolone already non-aromatizing + mild anti-E2; AI on top crashes E2 too low → joint pain, mood issues, lipid worsening.

Neutral / safe co-administration

  • Most non-hormonal nootropics (modafinil, citicoline, NAC, magnesium, fish oil — Dylan's V4) — no direct interaction; the issue is not pharmacological collision but the underlying inappropriateness of cosmetic AAS use in a healthy young eugonadal male combat athlete.
▸ Drug interactions deep dive
  • Warfarin / anticoagulants: AAS class generally potentiates warfarin effect — dose reduction required, frequent INR monitoring.
  • Insulin and oral hypoglycemics: Modest insulin sensitivity changes possible; monitor glucose in diabetic patients (AAS class general).
  • CYP-mediated metabolism: Drostanolone is partially CYP3A4-metabolized; strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) may modestly elevate exposure, but no clinically significant interaction documented for drostanolone specifically.
  • Hepatotoxicity: Drostanolone enanthate (injectable, not 17α-alkylated) has minimal hepatotoxicity vs oral 17α-alkylated AAS. Mild transaminase elevation possible at high doses but typically reversible and modest.
  • Detection (WADA): S1.1 Anabolic Androgenic Steroids, banned in- and out-of-competition. Detection via urine LC-MS/MS for parent + metabolites; long-ester injectable means weeks-to-months detection window depending on dose / duration / individual metabolism. Irrelevant for Dylan's untested status.
▸ Pharmacogenomics
  • AR (androgen receptor) CAG repeat length: Shorter CAG repeats = stronger AR signaling per unit ligand. Users with shorter repeats experience more pronounced androgenic side effects (hair loss, prostate, skin) at any given dose. Drostanolone is a potent peripheral androgen (DHT-class with 3α-HSD blocking) — for users with shorter CAG repeats and male-pattern baldness predisposition, this is one of the more aggressive AAS for hair loss specifically.
  • SRD5A2 (5α-reductase) variants: Mostly irrelevant for drostanolone since it's already DHT-class (not a 5α-reductase substrate).
  • CYP3A4 polymorphisms: Modestly affect metabolism but no clinical pharmacogenomic dosing guidance exists.
  • Practical note: No pharmacogenomic test changes the SKIP-AT-20 verdict. Verdict is driven by indication / risk balance, not metabolic variability. Dylan's June 2026 23andMe may include AR CAG / SRD5A2 SNPs but interpretation will not change the SKIP recommendation.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx (US) None N/A N/A No FDA-approved indication. Drolban (drostanolone propionate) was FDA-withdrawn decades ago. No legitimate Rx pathway exists.
Gray-market UGL (underground lab) Common offerings on bodybuilding forums, telegram channels, dark markets $60-100 / 10mL @ 200mg/mL Low-to-medium Frequently underdosed or counterfeit (substituted with cheaper testosterone enanthate or boldenone, sold at Masteron prices). Independent lab testing (Anabolic Lab, Janoshik) flags meaningful counterfeit / underdosed rates. Enanthate ester less commonly produced than propionate by major UGLs — supply quality varies more for "Mast E" specifically.
Pharmaceutical-grade gray-market Limited international pharmacy availability for legitimate brand $200-400 / 10mL Medium Higher quality than UGL but still gray-market; legal exposure varies.

For Dylan: Sourcing is solvable but irrelevant — the compound is not appropriate for any goal Dylan has. Skip the compound, do not engage the sourcing question.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Total + free testosterone, SHBG, LH, FSH, E2 (sensitive assay), DHT, prolactin, full lipid panel (LDL, HDL, total cholesterol, triglycerides, ApoB, ideally Lp(a)), ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, CBC (hematocrit), HbA1c, fasting glucose, eGFR, blood pressure, PSA, semen analysis (if fertility-relevant), echocardiogram if multi-cycle intent.
  • During use (week 4): ALT, AST, GGT, full lipid panel, blood pressure, hematocrit. Flag if HDL drops >50%, BP >140/90.
  • End of cycle: Full HPG panel (T, LH, FSH, E2, DHT) to quantify suppression; lipids; LFTs.
  • Post-cycle: HPG recovery check at week 4-8; full lipid recovery check at week 8-12.
  • Long-term (multi-cycle users): Annual lipid trends, periodic echocardiogram, formal CVD risk recalculation.
▸ Controversies / open debates Live debate

1. Is drostanolone genuinely "anti-estrogen" or is the reputation overstated?

Claim: Drostanolone has anti-estrogen properties, can substitute for AI in stack, was used as breast cancer treatment. Reality: Real but limited. The historical breast cancer indication is real but was abandoned for tamoxifen because tamoxifen does the job better. The "anti-estrogen" effect in modern bodybuilding stacks is mild — it does not substitute cleanly for anastrozole / letrozole when running aromatizing AAS at high doses, and the mechanism (peripheral AR/ER cross-talk + minor aromatase substrate competition) does not block aromatization elsewhere. The reputation is folk-amplified.

2. Cosmetic-AAS framing — useful or pejorative?

The framing of drostanolone as "purely cosmetic" is technically accurate (the only documented modern use case is contest-prep aesthetics) but is sometimes contested in bodybuilding circles. Counter-claims:

  • "Drostanolone improves training-induced hardness even off-stage" — true at low body fat, invisible at higher body fat.
  • "Drostanolone is mild and good for first cycles" — false; it's a specialty compound with poor cost-benefit for general physique enhancement vs testosterone alone.
  • "Drostanolone has anti-aging / longevity uses" — no evidence.

The cosmetic framing accurately captures the use case. It does not pejoratively diminish bodybuilding as a discipline; it simply identifies the compound's actual scope.

3. Brain-development concerns at 20

Same-family AAS concern: AR signaling is active in CNS regions including hippocampus, amygdala, and prefrontal cortex; supraphysiologic AAS exposure during ongoing prefrontal maturation (continues into mid-20s) is largely unstudied for cognitive endpoints. Behavioral / mood literature on adolescent AAS use shows elevated rates of mood disorder and aggression but is confounded. Precautionary case favors skip, particularly given Dylan's brain-priority framing. Drostanolone-specific data is sparser than testosterone-class compounds but the AR-mediated mechanism is the same.

4. Dylan-specificity

Even within the AAS skip-at-20 cluster, drostanolone is particularly Dylan-irrelevant:

  • Methenolone: at least nominally a "lean tissue" compound — could in theory be argued as a body-comp adder for an athletic profile (still skip at 20 same logic).
  • Oxandrolone: has FDA indications (HIV wasting, severe burn) — at least a real clinical compound (still skip for healthy 20yo).
  • Testosterone: the foundational HRT compound — has legitimate endocrine medicine use case at any age with documented hypogonadism.
  • Drostanolone: no clinical indication, no athletic performance benefit, purely a cosmetic specialty for stage aesthetics — addresses zero problems Dylan has.

For combat athletes specifically, "hardening" is not a goal. Combat sport rewards raw output (strength, speed, conditioning, recovery), brain-priority compounds (modafinil for film study, recovery sleep), and weight management (cutting weight with proper hydration / nutrition, not cosmetic vasculature). Drostanolone is structurally orthogonal to these goals.

▸ Verdict change log
  • 2026-05-04 (Encyclopedia v5) — SKIP-AT-20, listed in AAS skip-at-20 family.
  • 2026-05-06 (this file, medium-deep research) — SKIP-AT-20 MEDIUM confidence. Affirmed and deepened. Mechanism + evidence + cosmetic-AAS framing + Dylan-specificity all reviewed; no plausible benefit case for healthy 20yo MMA athlete with peak endogenous testosterone; same-family AAS risks (HPG suppression, atherogenic dyslipidemia worsened by non-aromatization, hair loss in predisposed users, gray-market supply) plus the additional point that drostanolone addresses a problem (stage aesthetics) Dylan does not and will not have. Verdict reverses ONLY for older bodybuilder in active contest preparation with medical supervision — clinically implausible for Dylan now or ever (combat sport ≠ bodybuilding).
▸ Open questions / gaps Open
  • Long-term cardiovascular outcomes in healthy young adults using cyclic drostanolone: No prospective cohort data; extrapolated from broader AAS literature.
  • Drostanolone-specific lipid impact magnitude: Sparser data than testosterone or oxandrolone; HDL crash is consistent with DHT-class but exact magnitude per dose less well-characterized.
  • Brain-development effects of supraphysiologic AR activation in 20-25yo prefrontal maturation window: Largely unstudied across AAS class.
  • Mechanism of "anti-estrogen" effect: Not fully characterized; appears mild and limited; does not substitute for AI in modern protocols.
  • Whether enanthate vs propionate ester makes any meaningful pharmacodynamic difference beyond pharmacokinetics: No, mechanism is identical; ester only affects half-life and dosing convenience.
▸ Cross-references

Same-family AAS skip-at-20 cluster:

  • methenolone — DHT-derivative AAS, "lean tissue" reputation, 1-methylated; SKIP-AT-20 same-family logic.
  • oxandrolone — 17α-alkylated DHT oral, "mild" reputation, FDA-approved for catabolic states; SKIP-AT-20 with HIGH confidence.
  • trenbolone — 19-nor, harsh cosmetic / strength compound; SKIP-AT-20 with strongest CNS-risk emphasis in family.
  • testosterone-cypionate — foundational AAS / HRT compound; SKIP-AT-20 absent documented hypogonadism.
  • methyltestosterone — 17α-alkylated oral testosterone, classic harsh oral; SKIP-AT-20 with strong hepatotoxicity emphasis.
▸ Sources (full, with our context)
  • Drolban (drostanolone propionate) — historical FDA approval / withdrawal — historical FDA pathway, breast cancer indication, withdrawal context
  • Drostanolone — Wikipedia — pharmacology overview, ester variants, historical use
  • Hartgens F, Kuipers H. (2004). "Effects of androgenic-anabolic steroids in athletes." Sports Medicine 34(8): 513-554. — Class overview including drostanolone, side effect profiles.
  • Kicman AT. (2008). "Pharmacology of anabolic steroids." British Journal of Pharmacology 154(3): 502-521. — Mechanism review including DHT-derivatives.
  • Llewellyn W. Anabolics (11th ed., 2017). — Reference text on drostanolone pharmacology, dosing, sourcing realities. Standard reference for AAS literature in bodybuilding/sports-medicine gray area.
  • Pope HG Jr et al. (2014). "Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement." Endocrine Reviews 35(3): 341-375. — Comprehensive AAS risk review including age-specific concerns.
  • Baggish AL et al. — Cardiovascular toxicity of illicit anabolic-androgenic steroid use, Circulation 2017 — Cardiac MRI long-term AAS users.
  • Rasmussen JJ et al. (2016). "Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation." PLoS One 11(8). — Persistent post-AAS hypogonadism documentation.
  • Anabolic Lab (anabolic.org) — Independent UGL/pharma testing data on AAS counterfeit rates including drostanolone.
  • WADA Prohibited List 2025 — S1.1 classification, AAS.
Back to compact view